The concept of using Mycobacterium for cancer treatment goes back to the 19th Century. Today, bacillus Calmette–Guerin (BCG) vaccine is a well-established treatment for human bladder cancer that ...

BCG is superior to chemotherapy as an adjuvant agent and is widely used following surgical resection of superficial bladder cancer. Mechanisms of Immune Interactions Between Mycobacteria ...

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive bladder cancer (NMIBC ...

Among patients with Bacillus Calmette-Guérin (BCG)-naïve, high-risk non-muscle invasive bladder cancer (NMIBC), treatment with the investigational anti-PD-1 monoclonal antibody sasanlimab, in ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

“Patients with BCG-naïve high-risk non-muscle invasive bladder cancer have high rates of recurrence and progression,” said Neal Shore, M.D., FACS, Medical Director for the Carolina Urologic ...

Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study (Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained ...